EFFECT OF SOME BIOLOGICAL AGENTS IN CLINICAL COURSE OF RHEUMATOID ARTHRITIS

Open Access Open Access
Restricted Access Subscription Access

Abstract


The aim of this study was to reveal DMARD’s (methotrexate) and biological agents (infliximab, rituximab) influence on the progression of bone erosions during the 54 weeks study period. Radiographic (based on MRI-data) erosion progression was stopped in infliximab and methotrexate treated subjects.

E A Trofimov

North-Western State Medical University named after I. I. Mechnikov

Email: trofimov-zeka@mail.ru

V I Mazurov

North-Western State Medical University named after I. I. Mechnikov

Member of the Russian Academy of Medical Sciences

V V Ripachev

North-Western State Medical University named after I. I. Mechnikov

  1. Влияние базисной терапии на деструкцию суставов при раннем ревматоидном артрите // Мат-лы V Северо-западной конференции по ревматологии. — СПб., 2005. — С. 52-54.
  2. Маслянский А. Л., Мазуров В. И., Боткин Е. Г. Анти-В-клеточная терапия аутоиммунных заболеваний // Мед. иммунология. — 2007. — Т. 9, № 1. — С. 15-34.
  3. Насонов Е. Л. Метотрексат. Перспективы применения в ревматологии. — М., 2009. — 196 с.
  4. Насонов Е. Л. Современные стратегии фармакотерапии ревматоидного артрита: место инфликсимаба // Consilium med. — 2006. — № 8. — С. 5-7.
  5. Балабанова Р. М. Новые возможности комбинированной терапии ревматоидного артрита: лефлуномид (Арава) и биологические агенты // Рус. мед. журн. — 2008. — Т. 29, № 12. — С. 1932.
  6. Keystone E., Emery P., Peterfy C. G. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study) // Ann. Rheum. Dis. — 2006. — Vol. 65, Suppl. 2. — P. 58.
  7. Ideguchi Н., Ohno Sh., Hattori H. Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs // Arthritis Res. Therapy. — 2006. — Vol. 8. — R76—78.
  8. Pavelka K., Gatterova J., Tegzova D. Radiografic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment // Clin. Exp. Rheumatol. — 2007. — Vol. 25, Suppl. 4. — P. 540—545.
  9. Cohen S. B., Greenwald M., Dougados M. R. Efficacy and safety of rituximab in active RA patients who experienced inadequate response to one or more anti-TNF-α therapies (REFLEX study) // Arthr. Rheum. — 2005. — Vol. 52, Suppl. 677.
  10. Ostergaard M., Peterfy C., Conaghan P. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRIacquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system // J. Rheumatol. — 2003. — Vol. 30. — P. 1385—1386.
  11. McQueen F. M., Dalbeth N. Predicting joint damage in rheumatoid arthritis using MRI scanning // Arth. Res. Therapy. — 2009. — Vol. 11. — P. 124.
  12. Maini R. N., Breedveld F. C., Kalden J. R. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate // Arthritis Rheum. — 2004. — Vol. 50. — P. 1051—1065.
  13. Rubbert-Roth A., Finckh A. Treatment options with rheumatoid arthritis failng initial TNF inhibitor therapy: a critical review // Arthr. Res. Ther— 2009. — Vol. 11, Suppl. 1. — S. 1.
  14. Tak P. P., Rigby W. F. C., Rubbert-Roth A. Rituximab in combination with methotrexate (MTX) significantly inhibits joint damage and improves clinical outcome in patients with early active RA who are naive to MTX: a randomized active comparator placebo-controlled trial (IMAGE) // Arthritis Rheum. — 2009. — Vol. 60, Suppl. 239. — P. 636.
  15. Puolakka K., Kautiainen H., Mottonen T. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial // Arthritis Rheum. — 2004. — Vol. 50. — P. 55-62.
  16. Emery P., Fleishmann R., Filipowicz-Sosnowska A. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial // Arthritis Rheum. — 2006. — Vol. 54. — P. 1390-1400.

Views

Abstract - 30

PDF (Russian) - 0

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2013 Trofimov E.A., Mazurov V.I., Ripachev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.